X4 Pharmaceuticals' Series B Round

X4 Pharmaceuticals raised a round of funding on November 15, 2017. Investors include Atlas Venture.

X4 Pharmaceuticals is a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment of refractory solid tumors. The company will deliver game-chang…

Articles about X4 Pharmaceuticals' Series B Round: